

University of Dundee

Eribulin treatment for patients with metastatic breast cancer

Jafri, Mariam; Kristeleit, Hartmut; Misra, Vivek; Baxter, Mark; Ahmed, Samreen; Jegannathen, Apurna

DOI:
[10.1159/000526140](https://doi.org/10.1159/000526140)

Publication date:
2022

Licence:
CC BY-NC

Document Version
Publisher's PDF, also known as Version of record

[Link to publication in Discovery Research Portal](#)

Citation for published version (APA):
Jafri, M., Kristeleit, H., Misra, V., Baxter, M., Ahmed, S., Jegannathen, A., Jain, A., Maskell, D., Barthakur, U., Edwards, G., Walter, H. S., Walshaw, R., Khan, M., Borley, A., & Rea, D. (2022). Eribulin treatment for patients with metastatic breast cancer: The UK Experience - A Multicenter Retrospective Study. *Oncology*, *100*(12), 666-673. <https://doi.org/10.1159/000526140>

General rights

Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Eribulin Treatment for Patients with Metastatic Breast Cancer: The UK Experience – A Multicenter Retrospective Study

Mariam Jafri^a Hartmut Kristeleit^b Vivek Misra^c Mark Baxter^d
Samreen Ahmed^e Apurna Jegannathan^f Ankit Jain^g David Maskell^h
Urmila Barthakurⁱ Gwenllian Edwards^j Harriet S. Walter^k Richard Walshaw^l
Madeha Khan^m Annabel Borleyⁿ Daniel Rea^{a, o}

^aMedical Oncology, University Hospitals Birmingham Foundation Trust, Birmingham, UK; ^bDepartment of Medical Oncology, Guy's and St Thomas' NHS Foundation Trust, London, UK; ^cClinical Oncology, The Christie NHS Foundation Trust, Cancer Centre, Manchester, UK; ^dMolecular and Clinical Medicine, Division of Molecular and Clinical Medicine, Ninewells Hospital and Medical School, University of Dundee, Dundee, UK; ^eMedical Oncology, University Hospitals of Leicester, Leicester, UK; ^fClinical Oncology, University Hospitals of North Midlands NHS Trust, Stoke-on-Trent, UK; ^gMedical Oncology, Royal Wolverhampton Hospitals NHS Trust, Wolverhampton, UK; ^hClinical Oncology, Norfolk and Norwich University Hospitals NHS Trust, Norwich, UK; ⁱClinical Oncology, Taunton and Somerset Foundation Trust, Taunton, UK; ^jOncology, Velindre University NHS Trust, Cardiff, UK; ^kDepartment of Oncology, University Hospitals of Leicester, Leicester, UK; ^lDivision of Cancer Sciences, The Christie NHS Foundation Trust, Cancer Centre, Manchester, UK; ^mOncology, Guy's and St Thomas' NHS Foundation Trust, London, UK; ⁿClinical Oncology, Velindre University NHS Trust, Cardiff, UK; ^oMedical Oncology, University of Birmingham Clinical Trials Unit, Birmingham, UK

Keywords

Eribulin · Observation study · Real-world data · Metastatic breast cancer · Older adults · Second-line treatment

Abstract

Introduction: This study examined real-world data from patients who received eribulin for metastatic breast cancer (MBC) collected from 14 hospitals across the UK. **Methods:** Anonymized data were collected retrospectively from patients with MBC who had received eribulin. The data included the hormone-receptor status, histological diagnosis, age, prior chemotherapy, response to eribulin, progression-free survival (PFS), and overall survival (OS). **Results:** Among 577 patients analyzed, the median age was 56 years, and most

patients (73%) were estrogen-receptor positive. The median OS was 288 days (95% confidence interval [CI]: 261–315), and the PFS was 117 days (95% CI: 105–129). The median OS was higher among older patients (≥ 65 vs. < 65 years: 325 days [95% CI: 264–385] vs. 285 days [95% CI: 252–317]; $p = 0.028$). The median OS was also higher in patients who received eribulin after fewer prior lines of chemotherapy (≤ 2 vs. > 2 prior: 328 days [95% CI: 264–385] vs. 264 days [95% CI: 229–298]; $p = 0.042$). **Discussion/Conclusion:** These retrospective data suggest that eribulin can be successfully used in older patients with MBC. Eribulin treatment was more effective in earlier-line settings, which, while predictable, supports consideration of eribulin as a second-line treatment option.

© 2022 The Author(s).
Published by S. Karger AG, Basel

Background

Metastatic breast cancer (MBC) is considered fairly common since 5–10% of patients with breast cancer present with de novo metastatic disease at diagnosis, and an additional 30% of breast cancer patients later develop metastases [1, 2]. Although there has been progress in the treatment of breast cancer, MBC remains a leading cause of cancer death in women worldwide. The median survival time ranges from 8 to 18 months for patients with triple-negative MBC [3, 4] and 3–5 years for those with hormone-receptor positive MBC [4, 5]. Management is challenging as the heterogeneous nature of MBC results in varying clinical outcomes and responses to therapy [6]. Unfortunately, deciding on an appropriate therapeutic sequence to treat MBC using evidence-based medicine results is difficult because many studies do not track post-progression treatment and response [6].

Eribulin is approved in the UK for the treatment of patients with locally advanced or MBC based on the results of 2 pivotal studies, EMBRACE and Study 301 [7, 8]. Eribulin is recommended for patients who have progressed after ≥ 1 line of chemotherapy for advanced disease, which should have included an anthracycline and a taxane [9]. The mechanisms of action for eribulin have been previously published [10–12]. Briefly, eribulin is a synthetic analog of halichondrin B and inhibits the growth phase of microtubules without inhibiting the shortening phase [13]. In the clinical setting, eribulin has been evaluated in heavily pretreated patients with MBC. In EMBRACE, patients had received two to five lines of prior chemotherapy [7], and in Study 301, patients had up to three lines of treatment [8]. In EMBRACE, eribulin was compared with physician's choice and was associated with an improved overall survival (OS) of 13.1 months (95% CI: 11.8–14.3) compared with 10.6 months (95% CI: 9.3–12.5; $p = 0.041$) [7]. Eribulin was not shown to be superior to capecitabine in Study 301 [8], but it was superior to vinorelbine in terms of PFS and ORR in Chinese women with pretreated MBC [14]. Although eribulin has shown promise as a treatment for patients with heavily pretreated MBC, its effects on patients in earlier stages of treatment are unknown. Since the patient populations in clinical trials (which must meet exact inclusion and exclusion criteria) are not entirely generalizable to the total population of patients with MBC [15–17], evaluation of eribulin in real-world settings is warranted.

There are few evaluations of eribulin in real-world settings, and most have focused on patients with heavily pretreated MBC [15–20]. However, there are some

data to support eribulin use in an earlier-line setting. A recent real-world study investigating the impact of eribulin on survival in patients with MBC found that patients with zero or one prior line(s) of therapy had improved OS (median 555 days; 95% CI: 475–568) compared with patients with three or more prior lines of therapy (median 383 days; 95% CI: 342–459) [21]. A study comparing the efficacy of eribulin for Taiwanese women with MBC found a trend toward an increase in the objective response rate in patients with fewer prior lines of treatment, although the difference was not significant [17].

The Cancer Drugs Fund in the UK was established in 2010 to aid in increasing access to cancer drugs that had not been or were in the process of being appraised by the National Health Service [22]. Eribulin was made available to patients via the Cancer Drugs Fund if they had received at least two prior lines of treatment. Patients who were human epidermal growth factor receptor 2 (Her2)-negative and had previously received at least one line of treatment for advanced disease could also qualify to receive eribulin through the Cancer Drugs Fund [23]. Most patients who have received eribulin in the UK thus far have received it after ≥ 2 lines of treatment. Here, we describe the demographics and survival profiles of patients who received eribulin for MBC in the UK using data from several different institutions treating a diverse population.

Methods

Study Design

This real-world study analyzed data from patients with MBC who had been treated with eribulin and was collected from 14 hospitals across the UK. The data were retrospective and obtained using computer and chemotherapy records. Data were collected on the initial histological diagnosis including histological subtype, tumor grade, receptor status (estrogen receptor [ER] and Her2), age, previous chemotherapy, response to eribulin, adverse events, OS, and progression-free survival (PFS). Adverse events were summarized as the presence or absence of nausea (any-grade severity), or severe (grade 3–4) neutropenia and neuropathy.

The data-collection plans received individual trust review board approval as audits of clinical services. The data were analyzed anonymously, and, therefore, informed consent was not required.

Statistical Methods

The OS and PFS were estimated using the Kaplan-Meier method. Significant differences and p values were calculated based on a Mantel-Cox log-rank test. Evaluations were performed using SPSS version 23 (IBM Corp., Armonk, NY, USA).




Fig. 1. Age distribution in the ITT population (a), the ER status (b), and the Her2 status (c) of the eribulin-treated patient cohort. ER, estrogen receptor; ITT, intent-to-treat; Her2, human epidermal growth factor receptor 2.

Results

Patient Demographics

Data were collected from 592 patients who received eribulin in specialist cancer centers, teaching hospitals, and cancer units throughout the UK between 2011 and 2017. Pharmacy records were used to identify and select patients who had received a previous line of treatment. Patient age distribution in the intent-to-treat (ITT) population is presented in Figure 1a. The efficacy analysis set

consisted of the data collected from 577 patients who received at least one complete cycle of eribulin. The median age of patients was 56 years (range, 33–84 years). Multiple types of MBC were represented: 129 patients had triple-negative MBC (22%); 419 (73%) were ER-positive, and 158 (27%) were ER-negative (Fig. 1b); 100 (17%) patients were Her2-positive, 475 (82%) were Her2-negative, and 1 patient had an unknown Her2 status (Fig. 1c). The majority of patients (80%) had ductal carcinoma of no special type.




Fig. 2. Sites of metastases (a) and the number of prior lines of chemotherapy (b) among the patient cohort. Some patients may have had more than 1 site of metastasis.

Burden of Disease

Patients had numerous sites of metastases, and some patients had multiple sites of metastases (Fig. 2a). Bone metastases were present in 351 patients (60.8%), lymph node metastases in 303 patients (52.5%), liver metastases in 262 patients (45.4%), and brain metastases in 65 patients (11.3%; Fig. 2a).

Prior Treatments

Patients had a median of 3 (range, 1–10) different types of chemotherapy treatments prior to receiving eribulin (Fig. 2b). The majority of patients had received prior taxanes (91%) and capecitabine (82%). The median

number of eribulin cycles received by patients was 5 (range, 1–29). Data on initial eribulin dosing was available for 209 patients (36.2%): the full, licensed, dose was given to 165 patients (78.9%), while an 80% dose was given to 36 patients (17.2%), and a 50% dose was given to 8 patients (3.8%). Of the patients for whom dosage information was available, 57 (27.3%) required a dose reduction during treatment with eribulin.

Efficacy

The median OS was estimated to be 288 days (95% CI: 261–315 days), and the median PFS was 117 days (95% CI: 105–129). Patients with triple-negative disease had




Fig. 3. Kaplan-Meier estimate of OS for patients with triple-negative MBC compared with patients with Her2/ER-positive MBC. “Her2/ER-positive” were those patients who were ER-positive and/or Her2-positive. ER, estrogen receptor; Her2, human epidermal growth factor receptor 2; MBC, metastatic breast cancer; OS, overall survival.

worse OS and PFS compared with patients with other disease types. The median OS for patients with triple-negative disease was 234 days (95% CI: 263–293), while the remainder of the MBC patient cohort had a median OS of 308 days (95% CI: 279–338; $p = 0.025$; Fig. 3). The median PFS for patients with triple-negative disease was 89 days (95% CI: 71.6–106.4), while the remaining patients had a median PFS of 132 days (95% CI: 116.1–147.9).

Burden of Disease

There was no significant difference in the OS or PFS of patients with liver or lung metastases. Patients with liver metastases had an OS of 299 days (95% CI: 259–339), and patients with lung metastases had an OS of 279 days (95% CI: 242–316). Patients with a brain metastasis had a decreased OS (221 days; 95% CI: 167–274) as compared with those without (279 days; 95% CI: 243–314; $p = 0.06$; Fig. 4).

Prior Lines of Chemotherapy

The median OS for patients receiving eribulin after ≤ 2 prior lines of chemotherapy was 328 days (95% CI: 264–385) compared with 264 days (95% CI: 229–298; $p = 0.042$; Fig. 5) for those who received > 2 prior lines of chemotherapy.




Fig. 4. Kaplan-Meier estimate of OS for patients with or without brain metastases. OS, overall survival.




Fig. 5. Kaplan-Meier estimate of OS for patients who had received > 2 lines of chemotherapy and for patients who had received ≤ 2 lines of chemotherapy before eribulin treatment (ITT population). ITT, intent-to-treat; OS, overall survival.

Age

The median OS in the ITT population for patients ≥ 65 years old was 325 days (95% CI: 264–385) compared with 285 days (95% CI: 252–317; $p = 0.028$) for those who were < 65 years old (Fig. 6).




Fig. 6. Kaplan-Meier estimate of OS for patients ≥ 65 years old compared with patients < 65 years old (ITT population). ITT, intent-to-treat; OS, overall survival.

Safety/Tolerability

The data reported that neuropathy events of grade 3–4 severity occurred in 11% of patients. Nausea (all grades) was experienced by 14% of patients, and neutropenia of grade 3–4 severity was reported for 19% of patients. No patients in this study were recorded as having a treatment-related death.

Discussion/Conclusion

This real-world data analysis, gathered from hospitals throughout the breadth of the UK, supports the use of eribulin as a second-line treatment in MBC. OS was improved when eribulin treatment was given at an earlier line (after ≤ 2 prior lines of chemotherapy) compared with a subsequent line. When administered to an unselected population, eribulin was associated with an OS approaching 1 year.

These data are a more representative sample of the general population than clinical trial data. Patients receiving treatment for MBC in the real world tend to be frailer (i.e., with more advanced disease or additional comorbidities) than those in the clinical trial setting [24, 25]. Both EMBRACE and Study 301 had inclusion criteria that required an Eastern Cooperative Oncology Group performance status of 0–2 and adequate liver function as

evidenced by bilirubin levels ≤ 1.5 times the upper limits of normal (ULN) and alkaline phosphatase, alanine aminotransferase, and aspartate aminotransferase levels $\leq 3 \times$ ULN (in the case of liver metastases, $\leq 5 \times$ ULN) [7, 8]. In this analysis, patients were also included from a wide range of hospitals, including specialized cancer centers in large cities, urban cancer units, and rural cancer units, which are not always encompassed in clinical trials.

The data are more generalizable and provide real-world expectations of outcomes for patients considering treatment with eribulin in the UK. The rationale was similar for other real-world studies related to eribulin treatment outcomes in India [15], Taiwan [17], and France [20]. Another important finding was that older patients (≥ 65 years old) had improved OS compared with those who were younger. Patients in EMBRACE had a median age of 55 years (range, 27–85), and only 19.8% of patients were aged 65 years or older. This real-world study had a patient population with a median age of 56 years and a greater representation of older patients (≥ 65 years old; 24%; $n = 141/591$). Prior investigations support the safety and efficacy of eribulin for older patients in a real-world setting [16, 26], and taken together, our data reassure that eribulin can be used successfully in older adult patients with MBC. This is an important consideration given that patients with breast cancer tend to be diagnosed at an older age, and currently, there is an increase in older patients with metastatic disease for whom evidence-based data are limited.

In a pooled post hoc analysis of EMBRACE and Study 301, eribulin nominally significantly improved OS versus the control treatment in patients with the following baseline metastases: bone, lymph node, liver, and chest wall/breast/skin [27]. In our study, patients with liver or lung metastases had similar OS and PFS. However, we did note worse outcomes for patients with MBC and brain metastases compared to those without brain metastases; similarly, worse outcomes were observed among patients with triple-negative disease compared to patients who had Her2/ER-positive disease. Notably, brain metastases and triple-negative disease are both generally associated with poorer patient outcomes. The data showed that patients with brain metastases had numerically reduced survival compared with patients with liver and/or lung metastases. The better survival outcomes for patients with liver and/or lung metastases may represent a broader improvement in these aspects of the multidisciplinary management of breast cancer. We also observed longer survival outcomes for patients treated with eribulin in the second-line compared with later-line settings. These results are

consistent with a previous study showing improvement in OS when eribulin was prescribed in patients who received fewer lines of treatment compared to control (capecitabine or treatment of the physician's choice) [28].

There are limitations to comparing real-world data with clinical trials. Response Criteria in Solid Tumors (RECIST) are not routinely used to assess tumors in the real-world clinical setting. Assessments are based on radiological assessments of response or progressive disease, and different criteria may be used by different clinicians. While there remains an ongoing need to improve outcomes in patients with MBC, our data support the use of eribulin as a second-line treatment for MBC.

Statement of Ethics

The data-collection plans received individual trust review board approval as audits of clinical services. This study involved the collection and analysis of anonymized data only, and, as such, it did not require any compliance with the Declaration of Helsinki. No ethics approval was needed for this research because this was a real-world/retrospective study using only anonymized data. No patients were directly involved. No identifiable individual patient data are contained in this publication; therefore, no permission was needed.

Conflict of Interest Statement

Dr. Mariam Jafri reports receiving personal fees from Eisai during the conduct of the study; personal fees from Roche, Pfizer, and Lilly, outside the submitted work. Dr. Samreen Ahmed reports receiving consultancy and advisory fees from Eisai. Dr. Annabel Borley reports personal fees from a commercial sponsor, outside the submitted work (i.e., an honorarium for participating in the Steering Committee for First Thoughts Educational Meeting 2018). Dr. Hartmut Kristeleit reports personal fees from Eisai during the conduct of the study; personal fees from Novartis and Roche; personal fees and other from Pfizer; and other from Daiichi-Sankyo, outside the submitted work. Dr. Vivek Misra reports personal fees

from Eisai UK, outside the submitted work. Dr. Daniel Rea reports nonfinancial support from Eisai and Novartis; personal fees from Roche, Novartis, Pfizer, and Lilly; grants from Roche, Biotheranostics, and RNA Diagnostics; and personal fees from Daiichi-Sankyo, outside the submitted work. Dr. Urmila Barthakur, Dr. Mark Baxter, Dr. Gwenllian Edwards, Dr. Ankit Jain, Dr. Apurna Jegannathen, Dr. Madeha Khan, Dr. David Maskell, Dr. Richard Walshaw, and Dr. Harriet S. Walter have nothing to disclose.

Funding Sources

Eisai Company Limited provided financial assistance for the statistical analysis of the data. Writing support was provided by Oxford PharmaGenesis Inc., Newtown, PA, USA and was funded by Eisai Inc., Nutley, NJ, USA. Role of the funding source: Eisai Company Limited provided financial assistance for the statistical analysis of the data. They were not involved in the study design/conception, development, analysis of data, or the writing of the manuscript. The authors had full access to the data and control of the final approval and decision to submit the manuscript.

Author Contributions

Study concepts, study design, data acquisition, and quality control of data and algorithms: Mariam Jafri. Data analysis and interpretation, manuscript preparation, manuscript editing, manuscript review, and approval of final draft for submission/responsibility for content: Mariam Jafri, Hartmut Kristeleit, Vivek Misra, Mark Baxter, Samreen Ahmed, Apurna Jegannathen, Ankit Jain, David Maskell, Urmila Barthakur, Gwenllian Edwards, Harriet S. Walter, Richard Walshaw, Madeha Khan, Annabel Borley, and Daniel Rea.

Data Availability Statement

The source data used in this analysis will not be made publicly available; however, the authors may consider sharing this information on a case-by-case basis to individual researchers upon request. Further inquiries can be directed to the corresponding author.

References

- 1 O'Shaughnessy J. Extending survival with chemotherapy in metastatic breast cancer. *Oncologist*. 2005;10(Suppl 3):20–9.
- 2 Cardoso F, Harbeck N, Fallowfield L, Kyriakides S, Senkus E; ESMO Guidelines Working Group. Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2012;23(Suppl 7):vii11–9.
- 3 Li CH, Karantza V, Aktan G, Lala M. Current treatment landscape for patients with locally recurrent inoperable or metastatic triple-negative breast cancer: a systematic literature review. *Breast Cancer Res*. 2019;21(1):143.
- 4 Vagia E, Mahalingam D, Cristofanilli M. The landscape of targeted therapies in TNBC. *Cancers*. 2020;12(4):916.
- 5 Caswell-Jin JL, Plevritis SK, Tian L, Cadham CJ, Xu C, Stout NK, et al. Change in survival in metastatic breast cancer with treatment advances: meta-analysis and systematic review. *JNCI Cancer Spectr*. 2018;2(4):pk062.
- 6 Bonotto M, Gerrata L, Poletto E, Driol P, Giangreco M, Russo S, et al. Measures of outcome in metastatic breast cancer: insights from a real-world scenario. *Oncologist*. 2014;19(6):608–15.
- 7 Cortes J, O'Shaughnessy J, Loesch D, Blum JL, Vahdat LT, Petrakova K, et al. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. *Lancet*. 2011;377(9769):914–23.

- 8 Kaufman PA, Awada A, Twelves C, Yelle L, Perez EA, Velikova G, et al. Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane. *J Clin Oncol*. 2015;33(6):594–601.
- 9 Halaven 0.44 mg/ml solution for injection [summary of product characteristics]. Hertfordshire, UK: Eisai Europe Limited; 2022.
- 10 Agoulnik SI, Kawano S, Taylor N, Oestreicher J, Matsui J, Chow J, et al. Eribulin mesylate exerts specific gene expression changes in pericytes and shortens pericyte-driven capillary network in vitro. *Vasc Cell*. 2014;6(1):3.
- 11 Funahashi Y, Okamoto K, Adachi Y, Semba T, Uesugi M, Ozawa Y, et al. Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models. *Cancer Sci*. 2014; 105(10):1334–42.
- 12 Yoshida T, Ozawa Y, Kimura T, Sato Y, Kuznetsov G, Xu S, et al. Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states. *Br J Cancer*. 2014;110(6):1497–505.
- 13 Jordan MA, Kamath K, Manna T, Okouneva T, Miller HP, Davis C, et al. The primary antimetastatic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. *Mol Cancer Ther*. 2005; 4(7):1086–95.
- 14 Yuan P, Hu X, Sun T, Li W, Zhang Q, Cui S, et al. Eribulin mesilate versus vinorelbine in women with locally recurrent or metastatic breast cancer: a randomised clinical trial. *Eur J Cancer*. 2019;112:57–65.
- 15 Bajpai J, Ramaswamy A, Gupta S, Ghosh J, Gulia S. Eribulin in heavily pretreated metastatic breast cancer: a tertiary care center experience from India. *Indian J Cancer*. 2016; 53(3):460–3.
- 16 de Nonneville A, Sabatier R, Goncalves A, Extra JM, Tarpin C, Launay S, et al. Safety and efficacy of eribulin for “real-world” older patients with metastatic breast cancer. *J Geriatr Oncol*. 2018;9(3):281–3.
- 17 Rau KM, Ou-Yang F, Chao TC, Kuo YL, Cheng TF, Chao TY, et al. Effect of eribulin on patients with metastatic breast cancer: multicenter retrospective observational study in Taiwan. *Breast Cancer Res Treat*. 2018; 170(3):583–91.
- 18 Garrone O, Montemurro F, Saggia C, La Verde N, Vandone AM, Airoidi M, et al. Eribulin in pretreated metastatic breast cancer patients: results of the TROTTER trial—a multicenter retrospective study of eribulin in real life. *Springerplus*. 2016;5:59.
- 19 Pedersini R, Vassalli L, Claps M, Tulla A, Rodella F, Grisanti S, et al. Eribulin in heavily pretreated metastatic breast cancer patients in the real world: a retrospective study. *Oncology*. 2018;94(Suppl 1):10–5.
- 20 Jacot W, Heudel PE, Fraisse J, Gourgou S, Guiu S, Dalenc F, et al. Real-life activity of eribulin mesylate among metastatic breast cancer patients in the multicenter national observational ESME program. *Int J Cancer*. 2019; 145(12):3359–69.
- 21 Takahashi M, Inoue K, Mukai H, Yamanaka T, Egawa C, Sakata Y, et al. Eribulin as first- or second-line chemotherapy for advanced or metastatic HER2-negative breast cancer: a real-world prospective study. *Ann Oncol*. 2018; 29(Suppl 8):viii90–121.
- 22 Aggarwal A, Fojo T, Chamberlain C, Davis C, Sullivan R. Do patient access schemes for high-cost cancer drugs deliver value to society?: lessons from the NHS Cancer Drugs Fund. *Ann Oncol*. 2017;28(8):1738–50.
- 23 York Health Economics Consortium. Cancer Drugs Fund (UK). 2016 [cited 2021 Jul 20]. Available from: <https://yhcc.co.uk/glossary/cancer-drugs-fund-uk/>.
- 24 Gyawali B, Parsad S, Feinberg BA, Nabhan C. Real-world evidence and randomized studies in the precision oncology era: the right balance. *JCO Precis Oncol*. 2017;1:1–5.
- 25 Statler A, Othus M, Erba HP, Chauncey TR, Radich JP, Coutre S, et al. Comparable outcomes of patients eligible vs ineligible for SWOG leukemia studies. *Blood*. 2018; 131(25):2782–8.
- 26 Muss H, Cortes J, Vahdat LT, Cardoso F, Twelves C, Wanders J, et al. Eribulin monotherapy in patients aged 70 years and older with metastatic breast cancer. *Oncologist*. 2014;19(4):318–27.
- 27 O’Shaughnessy J, Cortes J, Twelves C, Goldstein LJ, Alexis K, Xie R, et al. Efficacy of eribulin for metastatic breast cancer based on localization of specific secondary metastases: a post hoc analysis. *Sci Rep*. 2020;10(1):11203.
- 28 Cortes J, Twelves C. Impact of the number of prior chemotherapy regimens on outcomes for patients with metastatic breast cancer treated with eribulin: a post hoc pooled analysis. *Breast J*. 2020;26(7):1347–51.